Using advanced imaging to detect small bowel neuroendocrine tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effectiveness of 68Ga-DOTATOC PET/CT-enterography in identifying primary lesions in patients with small bowel neuroendocrine tumors. The study focuses on the importance of accurate staging and evaluation of disease burden, which are critical for determining appropriate treatment options. By utilizing a radiolabeled peptide that targets somatostatin receptors, the trial aims to improve imaging techniques compared to conventional methods. The goal is to enhance the detection of metastatic disease and tumor grading, which are vital prognostic factors.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* patients with small bowel neuroendocrine tumours
* tumors with any grade (from 1 to 3) and any Ki 67 percentage
* patients eligible for surgical resection

Exclusion Criteria:

* patients with synchronous other oncological disease
* patients with Inflammatory bowel disease
* patients Not eligible for surgery

Where it's running

• European Institute of Oncology
  Milan, Italy Recruiting

Study contacts

• Study coordinator: Luigi Funicelli, MD
• Email: luigi.funicelli@ieo.it
• Phone: +390294372725

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• External validation of the TB-NET score in advanced well‑differentiated neuroendocrine tumors

  This study tests whether the TB-NET score can predict progression-free survival in adults with advanced well-differentiated gastroenteropancreatic neuroendocrine tumors or lung carcinoids who have received systemic therapy.

  Recruiting at 11 sites Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz · Boston, Massachusetts and 10 other locations · NCT07903532

• Ultralow-dose PET imaging of somatostatin receptor 2 (SSTR2) uptake

  This study will test whether an ultralow-dose 68Ga-Dotatate PET scan on a high-sensitivity scanner can detect SSTR2 uptake in adults with and without neuroendocrine tumors.

  Recruiting Phase 2 Nuclear Imaging Institute · Englewood, New Jersey · NCT07284589

• How endocrine tumors develop resistance to alkylating chemotherapy

  This study will test whether patients with endocrine tumors who receive alkylating chemotherapy develop high tumor mutation rates and whether blood tests and imaging can detect those changes.

  Recruiting Uppsala University · Uppsala · NCT07121998

• Quality of life after surgery for neuroendocrine tumors

  This study looks at how surgery for neuroendocrine tumors affects the quality of life for patients to help improve their care after the operation.

  Recruiting Sunnybrook Health Sciences Centre · Toronto, Ontario · NCT06981455

• Removal of the primary small-intestine neuroendocrine tumor versus systemic therapy alone

  This project tries to see if removing the main small-intestine neuroendocrine tumor helps people with incurable metastatic disease live longer or avoid future problems, compared with treating them with systemic therapy alone.

  Recruiting Insel Gruppe AG, University Hospital Bern · Bern · NCT06787014

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.